The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Non-alcoholic fatty liver disease
Open accessAbstract
Non-alcoholic fatty liver disease has emerged a major challenge because of it prevalence, difficulties in diagnosis, complex pathogenesis, and lack of approved therapies. As the burden of hepatitis C abates over the next decade, non-alcoholic fatty liver disease will become the major form of chronic liver disease in adults and children and could become the leading indication for liver transplantation. This overview briefly summarizes the most recent data on the pathophysiology, diagnosis, and treatment of non-alcoholic fatty liver disease. Ongoing clinical trials are focused on an array of disease mechanisms and reviewed here are how these treatments fit into the current paradigm of substrate overload lipotoxic liver injury. Many of the approaches are directed at downstream events such as inflammation, injury and fibrogenesis. Addressing more proximal processes such as dysfunctional satiety mechanisms and inappropriately parsimonious energy dissipation are potential therapeutic opportunities that if successfully understood and exploited would not only address fatty liver disease but also the other components of the metabolic syndrome such as obesity, diabetes and dyslipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Nonalcoholic Fatty Liver Disease: A Systematic Review
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,267
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,819
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,285
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Self-citationRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818
Self-citationBariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
Lassailly, G., Caiazzo, R., Buob, D., Pigeyre, M., Verkindt, H., Labreuche, J., Raverdy, V., Leteurtre, E., Dharancy, S., Louvet, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.014 · Cited by 762
Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648 · cited 1×
“cirrhotic HCC occurs in patients with NAFLD compared to other causes of chronic liver disease [12].”
BackgroundInflammasome activation and function in liver disease
Szabo, G., & Petrasek, J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.94 · Cited by 597
Pathogenesis of Nonalcoholic Steatohepatitis
Machado, M. V., & Diehl, A. M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.066 · Cited by 539
Cassinotto, C., Boursier, J., de Lédinghen, V., Lebigot, J., Lapuyade, B., Cales, P., Hiriart, J., Michalak, S., Bail, B. L., Cartier, V., et al. (2016) · Hepatology · doi:10.1002/hep.28394 · Cited by 521
Ertunc, M. E., & Hotamisligil, G. S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r066514 · Cited by 488
Kwok, R., Choi, K. C., Wong, G. L.-H., Zhang, Y., Chan, H. L.-Y., Luk, A. O.-Y., Shu, S. S.-T., Chan, A. W.-H., Yeung, M.-W., Chan, J. C.-N., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309265 · Cited by 480
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
Boursier, J., Vergniol, J., Guillet, A., Hiriart, J.-B., Lannes, A., Le Bail, B., Michalak, S., Chermak, F., Bertrais, S., Foucher, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.023 · Cited by 400
Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
Zein, C. O., Yerian, L. M., Gogate, P., Lopez, R., Kirwan, J. P., Feldstein, A. E., & McCullough, A. J. (2011) · Hepatology · doi:10.1002/hep.24544 · Cited by 356
Sanyal, A. J., Friedman, S. L., McCullough, A. J., & Dimick‐Santos, L. (2015) · Hepatology · doi:10.1002/hep.27678 · Cited by 354
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Cui, J., Philo, L., Nguyen, P., Hofflich, H., Hernandez, C., Bettencourt, R., Richards, L., Salotti, J., Bhatt, A., Hooker, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.021 · Cited by 326
Sberna, A. L., Bouillet, B., Rouland, A., Brindisi, M. C., Nguyen, A., Mouillot, T., Duvillard, L., Denimal, D., Loffroy, R., Vergès, B., et al. (2018) · Diabetic Medicine · doi:10.1111/dme.13565 · Cited by 322
Koehler, E. M., Plompen, E. P. C., Schouten, J. N. L., Hansen, B. E., Darwish Murad, S., Taimr, P., Leebeek, F. W. G., Hofman, A., Stricker, B. H., Castera, L., et al. (2016) · Hepatology · doi:10.1002/hep.27981 · Cited by 321
Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis
Hirsova, P., Ibrabim, S. H., Gores, G. J., & Malhi, H. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r066357 · Cited by 270
Brown and beige fat: Molecular parts of a thermogenic machine
Cohen, P., & Spiegelman, B. M. (2015) · Diabetes · doi:10.2337/db15-0318 · Cited by 259
Peripheral Mechanisms in Appetite Regulation
Camilleri, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.016 · Cited by 214
Orci, L. A., Gariani, K., Oldani, G., Delaune, V., Morel, P., & Toso, C. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.04.036 · Cited by 209
Acosta, A., Camilleri, M., Shin, A., Vazquez-Roque, M. I., Iturrino, J., Burton, D., O’Neill, J., Eckert, D., & Zinsmeister, A. R. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.020 · Cited by 200
Loomba, R., Quehenberger, O., Armando, A., & Dennis, E. A. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p055640 · Cited by 197
Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
Kaswala, D. H., Lai, M., & Afdhal, N. H. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4079-4 · Cited by 172
Zhou, Y., Orešič, M., Leivonen, M., Gopalacharyulu, P. V., Hyysalo, J., Arola, J. T., Verrijken, A., Francque, S., Gaal, L. V., Hyötyläinen, T., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.05.046 · Cited by 168
Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD
Reeves, H. L., Zaki, M. Y. W., & Day, C. P. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4085-6 · Cited by 166
Natural History of Nonalcoholic Fatty Liver Disease
Goh, G. B., & McCullough, A. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4095-4 · Cited by 159
Bouret, S., Levin, B. E., & Ozanne, S. E. (2015) · Physiological Reviews · doi:10.1152/physrev.00007.2014 · Cited by 157
Zelber‐Sagi, S., Godos, J., & Salomone, F. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16638830 · Cited by 150
Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease
Hannah, W. N., & Harrison, S. A. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4153-y · Cited by 139
Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet
Abenavoli, L., Milic, N., Peta, V., Alfieri, F., Lorenzo, A. D., & Bellentani, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i45.16831 · Cited by 114
Africa, J. A., Newton, K. P., & Schwimmer, J. B. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4126-1 · Cited by 103
Decaris, M. L., Li, K. W., Emson, C. L., Gatmaitan, M., Liu, S., Wang, Y., Nyangau, E., Colangelo, M., Angel, T. E., Beysen, C., et al. (2016) · Hepatology · doi:10.1002/hep.28860 · Cited by 101
Noninvasive fatty liver markers predict liver disease mortality in the U.S. population
Ünalp–Arida, A., & Ruhl, C. E. (2015) · Hepatology · doi:10.1002/hep.28390 · Cited by 97
An Obesity-Predisposing Variant of the FTO Gene Regulates D2R-Dependent Reward Learning
Sevgi, M., Rigoux, L., Kuhn, A. B., Mauer, J., Schilbach, L., Hess, M. E., Gruendler, T. O. J., Ullsperger, M., Stephan, K. E., Brüning, J., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1589-15.2015 · Cited by 93
Ratziu, V., Bédossa, P., Francque, S., Larrey, D. G., Aithal, G. P., Serfaty, L., Voiculescu, M., Preoțescu, L., Nevens, F., de Lédinghen, V., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.040 · Cited by 56
Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis
Wree, A., Mehal, W. Z., & Feldstein, A. E. (2016) · Seminars in Liver Disease · doi:10.1055/s-0035-1571272 · Cited by 56
Yoneda, M., Thomas, E., Sclair, S. N., Grant, T. T., & Schiff, E. R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.03.014 · Cited by 52
Novel Pharmacotherapy Options for NASH
Ratziu, V. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4128-z · Cited by 48
Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis
Corey, K. E., & Rinella, M. E. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4083-8 · Cited by 44
(2016) · Hepatology · doi:10.1002/hep.28909 · Cited by 8
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationRisk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Targeting mitochondria-located circrna scar alleviates nash via reducing mros output
Zhao, Q., Liu, J., Deng, H., Ma, R., Liao, J.-Y., Liang, H., Hu, J., Li, J., Guo, Z., Cai, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.009 · Cited by 469
Xiao, J., Lim, L. K. E., Ng, C. H., Tan, D. J. H., Lim, W. H., Ho, C. S. H., Tan, E. X. X., Sanyal, A. J., & Muthiah, M. D. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.691696 · Cited by 94
Wang, S.-T., Zheng, J., Peng, H.-W., Cai, X.-L., Pan, X.-T., Li, H.-Q., Hong, Q.-Z., & Peng, X.-E. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01204-3 · Cited by 68
Metadata
- Authors
- Neuschwander-Tetri, B. A.
- Venue
- BMC Medicine
- Published
- 2017-02-28
- Volume
- 15
- Issue
- 1
- Pages
- 45-45
- ISSN
- 1741-7015 (ISSN-L)
- OpenAlex
- W2589458078
- Cited by
- 451
- References
- 53
- FWCI
- 27.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.